Stanford researchers are bringing a sci-fi vision to life aboard the International Space Station (ISS).
They have become the first to demonstrate that AI-based control can guide a robot autonomously in space. The research focuses on…
Author: admin
-
City of Legends — Photo Mode Contest
Calling all chooms! Looking for chrome fit for a legend?
We’re ending the year celebrating 5 years of Cyberpunk 2077 with something special for you: our City of Legends Photo Mode Contest!
The mission? Capture in a screenshot the heart of…
Continue Reading
-
Govt won’t allow foreign nationals to spread terrorism in country: Tariq Fazal – RADIO PAKISTAN
- Govt won’t allow foreign nationals to spread terrorism in country: Tariq Fazal RADIO PAKISTAN
- How Faiz’s hubris came undone with failure of TTP ‘resettlement project’ Dawn
- Ex-ISI chief jailed for 14 years The Express Tribune
- Vawda claims…
Continue Reading
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 December 2025
Seven new medicines recommended for approval
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its December 2025 meeting.
The committee recommended granting a conditional marketing authorisation for Anktiva (nogapendekin alfa inbakicept), for the treatment of adults with a type of bladder cancer that affects the lining of the bladder (non-muscle invasive bladder cancer, NMIBC) and that is at high risk of growing and spreading. Bladder cancer is one of the most common cancers in the European Union (EU), affecting over 200,000 people each year, with most cases being NMIBC. See more details in the news announcement in the grid below.
The CHMP recommended granting a marketing authorisation for Aumseqa (aumolertinib), for the treatment of EGFR-mutated non-small cell lung cancer.
Exdensur (depemokimab) received a positive opinion from the CHMP for the treatment of a particular type of asthma called severe eosinophilic asthma, and for severe chronic rhinosinusitis with nasal polyps, an inflamed lining of the nose and sinuses with swellings in the nose.
The CHMP adopted a positive opinion for Myqorzo (aficamten) for the treatment of adults with obstructive hypertrophic cardiomyopathy, a disease in which the muscle in the main pumping chamber of the heart becomes thickened or enlarged, which can block the flow of blood from the heart to the rest of the body.
The committee recommended granting a marketing authorisation for Mnexspike (COVID-19 mRNA vaccine), for the prevention of COVID-19 in people from 12 years of age.
The committee adopted positive opinions for two biosimilar medicines:
- Gotenfia (golimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis and ulcerative colitis.
- Ranluspec (ranibizumab), for the treatment of neovascular age-related macular degeneration, visual impairment and other retinopathies.
Negative opinion for one medicine
The committee recommended not granting a marketing authorisation for Blarcamesine Anavex (blarcamesine), a medicine intended for the treatment of Alzheimer’s disease. The CHMP concluded that the main study failed to demonstrate the effectiveness and safety of this medicine in patients with early Alzheimer’s disease who do not have mutations in the SIGMAR1 gene.
For more information on this negative opinion, see the question-and-answer document in the grid below.
Recommendations on extensions of therapeutic indication for 12 medicines
The committee recommended a change to extend the use of Mounjaro (tirzepatide) for the treatment of type 2 diabetes, that is not satisfactorily controlled, to adolescents and children from 10 years of age, together with diet and physical activity. In adults, Mounjaro is also used to treat type 2 diabetes and to help individuals with obesity (BMI of 30 kg/m2 or more) or who are overweight (BMI between 27 and 30 kg/m2) and who have weight-related health problems lose weight and keep their weight under control.
The committee recommended another 11 extensions of indication for medicines that are already authorised in the EU: Arexvy, Aspaveli, Dovprela, Elucirem, Eylea, Nucala, Recarbrio, Simponi, Uplizna, Vueway and Winrevair.
Withdrawal of application
An application for an initial marketing authorisation was withdrawn. Jelrix (autologous cartilage-derived articular chondrocytes, in-vitro expanded) was intended for the treatment of osteoporosis.
A question-and-answer document on the withdrawal of this medicine is available in the grid below.
Conclusion of referral
The committee finalised its review of the use of Melatomed following a disagreement among EU Member States regarding its authorisation. The Agency concluded that the benefits of Melatomed outweigh its risks, and that the marketing authorisation can be granted in Germany and in the other Member States of the EU where the company has applied for a marketing authorisation (Austria, Denmark and Sweden).
For more information, see the question-and-answer document in the grid below.
Other updates
The CHMP recommended changes to the existing contraindications of Vfend.
Agenda and minutes
The agenda of the December 2025 CHMP meeting is published on EMA’s website. Minutes of the meeting will be published in the coming weeks.
Continue Reading
-
US agents increasingly arresting Afghan asylum seekers, lawyers say: ‘A huge chilling effect’ | US immigration
Immigration agents appear to be increasingly arresting and detaining Afghan asylum seekers, especially men, who have arrived in the US recently and are awaiting court hearings to decide their cases.
Amir – an asylum seeker who came to the US via…
Continue Reading
-
BioRender Gives AI A Visual Language For Science
BioRender provides a rich set of tools for creating highly accurate images from biology. The tools provide a visual language to support AI in the biological domain.
BioRender
Notation and diagrams are essential elements of scientific communication….
Continue Reading
-
Comet Lemmon and Milky Way spotted over Hawaii photo of the day for Dec. 12, 2025
Comet C/2025 A6, better known as Comet Lemmon, was one of the latest icy visitors to swing through our neighborhood of the solar system, leaving astronomers and casual skywatchers equally delighted. For observers in Hawaii, the glow of the Milky…
Continue Reading
-
FC Bayern extend contracts of coaching team
Assistant coaches René Marić, Aaron Danks and Floribert Ngalula along with goalkeeping coach Michael Rechner have extended their contracts with FC Bayern until 30 June 2029. Head coach Vincent Kompany, who also signed a new deal until 2029 in…
Continue Reading
-
Can we save travel’s most beloved tradition?
Digital communication and social media let us stay in instant touch when we travel, but snail-mailed postcards are still uniting travellers.
It was a sweltering morning on the Thai island of Koh Chang and I was sitting at a cafe, sweating over a…
Continue Reading
-
Australia revises renewable energy forecasts for wind and transmissions
The announcement came as the Australian Energy Market Operator (AEMO) released a draft of its highly anticipated 2026 Integrated System Plan (ISP), in which it radically scaled back previous forecasts for wind generation and transmission line capacity.
Previously AEMO forecast that wind generation capacity should reach 42.6GW by the end of the decade. This has now been revised down to 26GW by 2030, 40GW by 2035 and 57GW by 2050. AEMO attributed the changes partly to elevated building costs, citing that solar was “somewhat cheaper and easier to build than wind” and “pairs well with storage”. The draft paper also highlights that offshore wind projects are approximately 40% more expensive to build and connect than onshore wind farms.
By contrast, AEMO now expects that 2GW of grid-scale solar will be needed by 2030 and 63GW by 2050, suggesting that solar will make a greater contribution to Australia’s energy mix in the coming years than previously thought. Additionally, AEMO has indicated that battery energy storage system (BESS) capacity will be 60% greater than previously forecast by 2030, with grid-scale operational BESS capacity being revised up from 15GW in the previous 2024 ISP, to 24GW.
The draft plan also revises AEMO’s previous forecasts for expanded transmission capacity. It estimates that a further 6,000km of transmission lines will need to be added to the existing 44,000km network by 2050, down from the previous estimate of 10,000km. The downgraded forecast is partly due to 365km of transmission lines having already been built and a further 2,800 km already committed or anticipated for other projects, as well as several projects having been abandoned. Delays to certain transmission project buildouts, and the decline in battery costs, have consequently meant BESS will serve as a buffer for slower transmission development. This means BESS will continue to serve as a central pillar of the National Energy Market (NEM) by providing system security such as frequency control, voltage stability and additional system strength.
The paper offers a roadmap for decarbonising Australia’s electricity system and underscores that “renewable energy firmed with storage, backed up by gas and connected by upgraded networks, presents the least-cost way to supply secure and reliable electricity to consumers, while meeting government policies.”
By 2025, it estimates that Australia will need a total of 120GW of combined grid-scale wind and solar, 32GW grid-scale batteries, 14GW of flexible gas and 12GW of pumped hydro to meet its energy needs. AEMO expects that electricity consumption required for industry, business and transport will nearly double to 389Twh by 2050, partly fuelled by rising demand from new energy-intensive industries such as data centres.
Although, like other nations, Australia has been retiring coal-fired plants in line with net zero goals, the draft plan indicates that the country will still rely on coal-fired generators “to main grid security and stability” until 2049.
Leanne Olden, an expert in energy law at Pinsent Masons, said the revised forecasts would be particularly relevant to businesses involved in wind farm development and transmission networks. “It is significant that AEMO is now slashing its forecast for the amount of wind, as well as transmission, that will be required as this was an expected major source of investment,” she said. “Clients will want to be aware that not as many projects will need to be built as was previously anticipated, or that different technologies may be preferred.”
“The draft ISP does however demonstrate Australia’s ongoing commitment to the transition to renewable energy, which should give comfort to those looking to invest in the country,” she added.
The AEMO has also launched a consultation seeking further industry feedback on its roadmap until 13 February 2026 ahead of publishing the final ISP in June next year.
Continue Reading